EDAP Achieves 7% Share in French Public Market Prior to Reimbursement
EDAP Achieves 7% Share in French Public Market Prior to Reimbursement
"Even ahead of reimbursement approval Ablatherm-HIFU is already earning a
strong position due to its clinical outcomes and low side effects," said
Pierre Reboul, Director of Sales for
"This market share in
In addition, in its
"With 26 of the top 50 centers already using our technology, this study
clearly demonstrates the full recognition of Ablatherm-HIFU as a valid option
for prostate cancer among Urologists, whereas only 7 centers are using a
brachytherapy option," commented Oczachowski. "Moreover, this survey being
carried out among the most prestigious reference French University Centers,
featuring key opinion leaders, definitely grants a scientific and academic
recognition of the Ablatherm-HIFU as solution to prostate cancer, despite the
therapy not being reimbursed yet. This validation will help to further expand
on HIFU business in
About EDAP TMS S.A.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).
For more information on the Company, contact Magnolia Investor Relations at (972) 801-4900, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com and http://www.hifu-planet.com.
To sign up for alerts please visit http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0
In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties. These include
statements regarding the Company's growth and expansion plans. Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in these forward-looking statements. Factors that may
cause such a difference include, but are not limited to, those described in
the Company's filings with the Securities and Exchange Commission.
Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or
marketed in the
CONTACT: EDAP TMS S.A. Magnolia Investor Relations
Blandine Confort Matt Kreps +33 4 78 26 40 46 972 801 4900
SOURCE EDAP TMS S.A.